Boston Scientific shared the 3-year MAJESTIC DES data online at CardioVascular and Interventional Radiology
MAJESTIC 3-Year Data Published for Boston Scientific’s Eluvia DES, by Endovascular Today
October 11, 2017—The 3-year results of the MAJESTIC first-in-human study of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) for treating femoropopliteal artery lesions were published by Stefan Müller-Hülsbeck, MD, et al online in CardioVascular and Interventional Radiology. The data were recently presented at CIRSE 2017, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe held September 16–20 in Copenhagen, Denmark.
As summarized in CardioVascular and Interventional Radiology, the prospective, single-arm, multicenter clinical trial enrolled 57 patients with symptomatic lower limb ischemia (Rutherford category 2, 3, or 4) and lesions in the superficial femoral artery or proximal popliteal artery. The mean lesion length was 70.8 ± 28.1 mm, and 46% of lesions were occlusions.
Read the full article at Endovascular Today
